Updated: 26th June 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder & CEO)
Why the Latest MDCG Guidance Matters
The newest MDCG guidance on clinical evaluation raises expectations again. Manufacturers must now demonstrate a living system of data appraisal, performance verification, and post-market follow-up that evolves with every design change and complaint.
Recent MDCG guidance reinforces that Clinical Evaluation should be maintained as a continuous lifecycle activity rather than a one-time regulatory exercise. Manufacturers are expected to demonstrate that Clinical Evaluation Reports (CERs) remain aligned with current scientific knowledge, Post-Market Clinical Follow-up (PMCF), Post-Market Surveillance (PMS), Risk Management and the General Safety and Performance Requirements (GSPRs).
As a result, Notified Bodies increasingly assess not only the quality of the Clinical Evaluation Report itself, but also how effectively it integrates with the wider Technical Documentation and Quality Management System.
Need an Introduction to Medical Device Clinical Evaluation?
This article focuses on clinical evaluation under the MDR and recent MDCG expectations. If you're looking for a complete overview of medical device clinical evaluation, including Clinical Evaluation Plans, Clinical Evaluation Reports, clinical evidence, PMS and PMCF requirements, read our Complete Guide to Medical Device Clinical Evaluation.
What Is Clinical Evaluation Under MDR?
Under Annexe XIV Part A of the EU MDR 2017/745 regulation, clinical evaluation means “a systematic and planned process to continuously generate, collect and appraise clinical data to verify the safety and performance of a device throughout its lifecycle.”
In practice, MDR replaces the static, pre-market model of the MDD with a dynamic, lifecycle approach that links four documents in sequence:
- Clinical Evaluation Plan (CEP) – defines methodology, endpoints, and sources.
- Clinical Data Collection – from studies, literature, or post-market use.
- Clinical Evaluation Report (CER) – evaluates data quality and draws conclusions.
- Post-Market Clinical Follow-Up (PMCF) – ensures findings remain valid in real-world use.
Key Changes in MDCG Guidance on Clinical Evaluation
Recent MDCG guidance does not fundamentally change the principles of Clinical Evaluation established under the EU MDR. Instead, it provides greater clarity regarding how manufacturers should demonstrate compliance and what evidence Notified Bodies increasingly expect during conformity assessment.
Several themes have emerged consistently across recent guidance and regulatory reviews.
Greater Emphasis on Demonstrating Clinical Benefit
Recent MDCG guidance places greater emphasis on demonstrating measurable clinical benefit rather than simply presenting clinical evidence. Manufacturers should be able to show not only that their device is safe, but also that it delivers meaningful clinical outcomes for its intended patient population. Clinical claims should be supported by objective evidence that is proportionate to the device’s classification, intended purpose and level of clinical risk.
Stronger Expectations for Equivalence
Using clinical evidence from equivalent devices has become considerably more challenging under the EU MDR. Manufacturers are expected to demonstrate technical, biological and clinical equivalence using robust supporting evidence. Where access to sufficient technical documentation cannot be obtained, additional PMCF activities or clinical investigations may be necessary to generate the required evidence.
Greater Integration of PMCF
Recent guidance reinforces that PMCF should directly address uncertainties or evidence gaps identified during the Clinical Evaluation. PMCF is no longer viewed as an isolated regulatory activity but as a primary mechanism for maintaining current clinical evidence throughout the product lifecycle.
Increased Focus on Consistency
Notified Bodies increasingly review Clinical Evaluation alongside Risk Management, PMS, PMCF, Instructions for Use, labelling and the wider Technical Documentation. Manufacturers should therefore ensure that intended purpose, clinical claims, benefit-risk conclusions and residual risks remain consistent across all regulatory documentation.
Clinical Evidence Requirements Under EU MDR
Annex XIV and Article 61 describe the hierarchy of acceptable evidence:
- Clinical investigations – gold-standard, prospective studies.
- Published literature – peer-reviewed data of suitable quality.
- Post-market data and registries – real-world evidence under PMS/PMCF.
- Equivalence justification – only if full access to source data exists.
The rule is proportionality: higher-risk devices require direct, device-specific data. Notified Bodies now expect clear traceability between evidence sources and device claims, with statistical justification and alignment across CER, Instructions for Use (IFU), and PMS reports.
The Clinical Evaluation Report (CER) – Structure and Strategy
What a CER must contain
A compliant CER includes:
- Device description and intended purpose
- Clinical data identification and appraisal
- Analysis of benefit–risk profile
- Correlation with risk-management and PMS findings
- Conclusions and update schedule
The CER must be a living document, reviewed at least annually for Class III and IIb implants or whenever new safety information arises.
Common CER non-conformities
- Unsupported data sources or outdated literature
- Reliance on MDD-era equivalence
- Poor linkage to CAPA or risk management
- Mismatch between CER conclusions, IFU claims, and PMS data
Tips for alignment
Map content to MDCG 2020-13 and the latest 2024-x update, ensure every claim has verifiable data, and link conclusions directly to PMS and PMCF outputs.
See also: Patient Guard’s Clinical Evaluation and CER Writing Services
Equivalence Under MDR: Stricter, Clearer, and Harder to Prove
Equivalence once allowed MDD manufacturers to piggyback on similar devices. Under MDR, that shortcut has virtually disappeared.
Per MDCG 2020-5 and 2020-6, manufacturers must demonstrate:
- Technical equivalence – same design and materials.
- Biological equivalence – same contact type and duration.
- Clinical equivalence – same intended purpose and clinical performance.
Access to the other manufacturer’s technical documentation is required—a condition rarely met without cooperation agreements. As a result, many legacy devices now require new clinical investigations or enhanced PMCF studies to remain on the market.
Post-Market Clinical Follow-Up (PMCF) and Continuous Evaluation
PMCF is the ongoing form of clinical evaluation in real-world use. It collects data on safety, performance, and residual risks identified during pre-market assessment.
The 2024 EU Commission/Team-NB review found that over 50 % of PMCF plans failed to close identified evidence gaps, even after multiple review rounds—making PMCF a top driver of CER non-compliance.
Effective PMCF plans must:
- Specify measurable objectives and justified sample sizes.
- Integrate statistical analysis plans.
- Demonstrate feedback into PMS and risk management.
See also: Patient Guard’s blog article on How to Navigate the EU & UK MDR: A Practical Compliance Guide
Clinical Evaluation Documentation and Lifecycle Integration
Clinical evaluation is not a standalone activity; it is woven through the device lifecycle:
CEP → Clinical Data → CER → PMCF → PMS → Risk Management
A risk-based QMS ensures each output feeds the next. For example:
- Risk files inform clinical study design.
- PMCF findings update risk evaluation.
- Management reviews confirm the effectiveness of risk controls.
Visualising this “evidence ecosystem” helps founders understand that clinical evaluation isn’t a regulatory hurdle but a continuous learning loop improving both safety and market credibility.
Practical Steps to Align with Current MDCG Expectations
Manufacturers preparing for MDR conformity assessment or updating existing Clinical Evaluation Reports should regularly review their clinical evidence against the latest MDCG guidance. Establishing a structured review process helps ensure Clinical Evaluation remains current and continues to support the device’s safety, clinical performance and benefit-risk profile.
Practical actions include:
- Review existing Clinical Evaluation Reports against current MDCG guidance.
- Update literature searches to include recently published clinical evidence.
- Reassess equivalence justifications where applicable.
- Ensure PMCF activities address identified evidence gaps.
- Verify consistency between the CER, Risk Management File, PMS documentation and labelling.
- Maintain documented review records and version histories.
- Update the CER whenever significant new evidence becomes available.
Preparing for 2025 Notified Body Reviews
During conformity assessment, Notified Bodies increasingly expect manufacturers to demonstrate that Clinical Evaluation is fully integrated within the wider Quality Management System rather than existing as a standalone document.
Areas commonly reviewed include:
- Current and reproducible literature search strategies.
- Objective critical appraisal of clinical evidence.
- Clear demonstration of measurable clinical benefit.
- Appropriate justification where equivalence is claimed.
- Integration between the CER, PMCF, PMS and Risk Management.
- Consistency between Technical Documentation, labelling and clinical claims.
- Evidence that Clinical Evaluation is actively maintained throughout the product lifecycle.
Manufacturers that maintain well-structured, evidence-based Clinical Evaluation Reports are generally better prepared for conformity assessment and subsequent surveillance audits.
Conclusion
The MDR transformed clinical evaluation from a pre-market formality into a continuous, data-driven discipline. Compliance now demands agility: living CERs, proactive PMCF, and tight integration with risk and quality systems.
Manufacturers who invest early in structured processes not only pass audits more smoothly—they build enduring trust with regulators, clinicians, and patients.
Contact Patient Guard for end-to-end support—from Clinical Evaluation Plans to full CER and PMCF implementation.
Frequently Asked Questions About MDCG Clinical Evaluation Guidelines
MDR requires continuous lifecycle evaluation, more substantial evidence for clinical benefit, and mandatory linkage between CER, PMCF, and PMS. The MDD’s one-time submission model no longer applies.
MDCG 2020-13 (CER Template), MDCG 2020-5/6 (Equivalence), MDCG 2024-x (update on evidence depth), and MDCG 2020-7 (PMCF methods) remain essential references.
At least annually for high-risk devices or immediately following significant design, safety, or performance changes.
Clinical investigations, peer-reviewed studies, post-market data, or properly justified equivalence with full access to source technical information.
They expect documented proof of technical, biological, and clinical similarity, plus direct access to the other device’s technical file—rarely achievable without formal agreements.
Yes. Patient Guard’s clinical team supports everything from planning and gap analysis to complete CER authoring and PMCF execution, aligned to the latest MDCG guidance.
Although MEDDEV 2.7/1 Rev. 4 was developed under the Medical Devices Directive (MDD), many of its principles relating to literature searches, critical appraisal and Clinical Evaluation methodology remain relevant where they do not conflict with the EU MDR. Manufacturers should always prioritise the requirements of Regulation (EU) 2017/745 together with the latest MDCG guidance.
Manufacturers should consider the latest MDCG guidance relevant to Clinical Evaluation, PMCF, equivalence, clinical investigations and Technical Documentation. The applicable guidance will depend on the type of medical device, its classification and the specific clinical evidence being evaluated.
References
This guide is based on the following legislation and official regulatory guidance relating to clinical evaluation, clinical evidence, equivalence, Post-Market Clinical Follow-up and Notified Body assessment under Regulation (EU) 2017/745 (MDR).
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/745 on Medical Devices (MDR) | Provides the legal framework for clinical evaluation under Article 61 and Annex XIV, including clinical evidence, Clinical Evaluation Plans, Clinical Evaluation Reports, equivalence, clinical investigations and Post-Market Clinical Follow-up. |
| European Commission | MEDDEV 2.7/1 Rev. 4 – Clinical Evaluation: A Guide for Manufacturers and Notified Bodies | Provides the established methodology for planning, conducting, documenting and updating clinical evaluations, including literature searching, appraisal of clinical data, analysis of clinical evidence and preparation of Clinical Evaluation Reports. Relevant sections continue to be applied under the MDR where consistent with current legislation and MDCG guidance. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-5 – Guidance on Clinical Evaluation and Equivalence | Explains how manufacturers should assess and document technical, biological and clinical equivalence when relying upon data from an equivalent device within a clinical evaluation. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-6 – Guidance on Sufficient Clinical Evidence for Legacy Devices | Explains how manufacturers of legacy devices should determine and justify the quantity and quality of clinical evidence required to demonstrate conformity with the MDR. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-7 – Post-Market Clinical Follow-up Plan Template | Provides an official structure for planning PMCF activities intended to confirm continued safety, clinical performance and benefit-risk acceptability and to address evidence gaps identified through clinical evaluation. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-13 – Clinical Evaluation Assessment Report Template | Provides the template used by Notified Bodies to document their assessment of a manufacturer's clinical evaluation, including the Clinical Evaluation Plan, literature review, equivalence, clinical investigations, PMS, PMCF and overall clinical evidence. |
| European Commission | MDCG Endorsed Documents and Other Guidance | Provides the official European Commission repository for current MDCG guidance, enabling manufacturers to check for newly published, revised or archived clinical-evaluation guidance. |
Clinical evaluation requirements and regulatory expectations continue to evolve. Manufacturers should always consult the latest published legislation and official MDCG guidance when preparing, reviewing and maintaining Clinical Evaluation Plans, Clinical Evaluation Reports and Post-Market Clinical Follow-up documentation.
Patient Guards Recent Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
Trustindex verifies that the original source of the review is Google. 
Trustindex verifies that the original source of the review is Google. 
Trustindex verifies that the original source of the review is Google. 
Trustindex verifies that the original source of the review is Google. 
Trustindex verifies that the original source of the review is Google. 
